Page 346 - Hematology_ Basic Principles and Practice ( PDFDrive )

284.e4 Part III Immunologic Basis of Hematology

139. Turner M: Molecules which recognize antigens. In Roitt IM, Brostoff 165. Asghar SS: Pharmacological manipulation of the complement system
J, Male DK, editors: Immunology, London, 1989, Gower, p 51. in human diseases. Front Biosci 1:e15, 1996.
140. Harris LJ, Larson SB, Hasel KW, et al: The three-dimensional struc- 166. Meissner HC, Leung DY: Immunoglobulin therapy in Kawasaki
ture of an intact monoclonal antibody for canine lymphoma. Nature syndrome and RSV prophylaxis. Front Biosci 1:e55, 1996.
360:369, 1992. 167. Rosen FS: Putative mechanisms of the effect of intravenous gamma-
141. Alt FW, Blackwell TK, Yancopoulos GD: Development of the primary globulin. Clin Immunol Immunopathol 67:S41, 1993.
antibody repertoire. Science 238:1079, 1987. 168. Anthony RM, Kobayashi T, Wermeling F, et al: Intravenous gam-
142. Golub ES: Immunology: A synthesis, Sunderland, MA, 1987, Sinaur. maglobulin suppresses inflammation through a novel T(H)2 pathway.
143. Krapp S, Mimura Y, Jefferis R, et al: Structural analysis of human Nature 475:110, 2011.
IgG-Fc glycoforms reveals a correlation between glycosylation and 169. Hamrock DJ: Adverse events associated with intravenous immuno-
structural integrity. J Mol Biol 325:979, 2003. globulin therapy. Int Immunopharmacol 6:535, 2006.
144. Nimmerjahn F, Ravetch JV: Fcgamma receptors: Old friends and new 170. Schulman Ronca and Bucuvalas, Inc., editor: Treatment experiences
family members. Immunity 24:19, 2006. and preferences of patients with primary immune deficiency disease: First
145. Parekh RB, Dwek RA, Sutton BJ, et al: Association of rheumatoid national survey, Towson, 2003, Immune Deficiency Foundation.
arthritis and primary osteoarthritis with changes in the glycosylation 171. Boschetti N, Stucki M, Späth PJ, et al: Virus safety of intravenous
pattern of total serum IgG. Nature 316:452, 1985. immunoglobulin: Future challenges. Clin Rev Allergy Immunol 29:333,
146. Holland M, Yagi H, Takahashi N, et al: Differential glycosylation of 2005.
polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients 172. Siegel J: Safety considerations in IGIV utilization. Int Immunopharmacol
with ANCA-associated systemic vasculitis. Biochim Biophys Acta 6:523, 2006.
1760:669, 2006. 173. Shelton BK, Griffin JM, Goldman FD: Immune globulin IV therapy:
147. Kaneko Y, Nimmerjahn F, Ravetch JV: Anti-inflammatory activity Optimizing care of patients in the oncology setting. Oncol Nurs Forum
of immunoglobulin G resulting from Fc sialylation. Science 313:670, 33:911, 2006.
2006. 174. Miller JL, Petteway SR, Jr, Lee DC: Ensuring the pathogen
148. Boshkov LK, Kelton JG: Use of intravenous gammaglobulin as an safety of intravenous immunoglobulin and other human plasma-
immune replacement and an immune suppressant. Transfus Med Rev derived therapeutic proteins. J Allergy Clin Immunol 108:S91,
3:82, 1989. 2001.
149. Eibl MM: Intravenous immunoglobulins in neurological disorders: 175. Van Holten RW, Autenrieth S, Boose JA, et al: Removal of prion chal-
Safety issues. Neurol Sci 24:S222, 2003. lenge from an immune globulin preparation by use of a size-exclusion
150. Eibl MM, Wedgwood RJ: Intravenous immunoglobulin: A review. filter. Transfusion 42:999, 2002.
Immunodefic Rev 1:S1, 1989. 176. Centers for Disease Control and Prevention (CDC): Renal insufficiency
151. Kistler P, Nitschmann H: Large scale production of human plasma frac- and failure associated with immune globulin intravenous therapy—
tions. Eight years experience with the alcohol fractionation procedure United States, 1985-1998. MMWR Morb Mortal Wkly Rep 48:518,
of Nitschmann, Kistler and Lergier. Vox Sang 7:414, 1962. 1999.
152. Oncley JL, Melin M, et al: The separation of the antibodies, isoag- 177. Brannagan TH, 3rd, Nagle KJ, Lange DJ, et al: Complications of
glutinins, prothrombin, plasminogen and beta1-lipoprotein into intravenous immune globulin treatment in neurologic disease. Neurol-
subfractions of human plasma. J Am Chem Soc 71:541, 1949. ogy 47:674, 1996.
153. Buchacher A, Iberer G: Purification of intravenous immunoglobulin 178. Caress JB, Cartwright MS, Donofrio PD, et al: The clinical features
G from human plasma—aspects of yield and virus safety. Biotechnol J of 16 cases of stroke associated with administration of IVIg. Neurology
1:148, 2006. 60:1822, 2003.
154. Gelfand EW: Differences between IGIV products: Impact on clinical 179. Stangel M, Muller M, Marx P: Adverse events during treatment with
outcome. Int Immunopharmacol 6:592, 2006. high-dose intravenous immunoglobulins for neurological disorders. Eur
155. Martin TD: IGIV: Contents, properties, and methods of industrial Neurol 40:173, 1998.
production—evolving closer to a more physiologic product. Int Immu- 180. Dalakas MC: High-dose intravenous immunoglobulin and serum vis-
nopharmacol 6:517, 2006. cosity: Risk of precipitating thromboembolic events. Neurology 44:223,
156. McIver J, Grady GF: Immunoglobulin preparations. In Kurtz SR, 1994.
Churchill WH, editors: Transfusion medicine, 1990, Blackwell Scien- 181. WHO: Use of convalescent whole blood or plasma collected from patients
tific, p 189. recovered from Ebola virus disease for transfusion, as an empirical treatment
157. Snydman DR, Werner BG, Heinze-Lacey B, et al: Use of cyto- during outbreak, 2014, World Health Organization.
megalovirus immune globulin to prevent cytomegalovirus disease in 182. Kohler G, Milstein C: Continuous cultures of fused cells secreting
renal-transplant recipients. N Engl J Med 317:1049, 1987. antibody of predefined specificityt. Nature 256:495–497, 1975.
158. Casadevall A, Scharff MD: Return to the past: The case for antibody- 183. Lonberg N, Huszar D: Human antibodies from transgenic mice. Int
based therapies in infectious diseases. Clin Infect Dis 21:150, 1995. Rev Immunol 13(1):65–93, 1995.
159. Intravenous immunoglobulin: Prevention and treatment of disease. 184. Hrabovska A, Bernard V, Krejci E: A novel system for the efficient
Summary of the NIH Consensus Development Conference. Transfus generation of antibodies following immunization of unique knockout
Med Rev 5:171, 1991. mouse strains. PLoS ONE 5(9):e12892, 2010.
160. Darabi K, Abdel-Wahab O, Dzik WH: Current usage of intravenous 185. Ahmad Z, Yeap S, Ali A, et al: scFv antibody principles and clinical
immune globulin and the rationale behind it: The Massachusetts application. Clin Dev Immunol 21012:1–15, 2012.
General Hospital data and a review of the literature. Transfusion 46:741, 186. Dantas-Barbosa C, de Macedo Brigido M, Maranhao AQ: Antibody
2006. phage display libraries: contributions to oncology. Int J Mol Sci
161. Kumar A, Teuber SS, Gershwin ME: Intravenous immunoglobulin: 13:5420–5440, 2012.
Striving for appropriate use. Int Arch Allergy Immunol 140:185, 2006. 187. Hammers C, Stanley J: Antibody phage display: Technique and applica-
162. Bayary J, Dasgupta S, Misra N, et al: Intravenous immunoglobulin tions. J Invest Dermatol 134:e17, 2014.
in autoimmune disorders: An insight into the immunoregulatory 188. Nixon A, Sexton D, Lander R: Drugs derived from phage display:
mechanisms. Int Immunopharmacol 6:528, 2006. from candidate indentification to clinical practice. MAbs 6:73–85,
163. Dalakas MC: Mechanisms of action of IVIg and therapeutic con- 2014.
siderations in the treatment of acute and chronic demyelinating 189. Pansri P, Jaruseranee N, Rangnoi K, et al: A compact phage display
neuropathies. Neurology 59:S13, 2002. human scFv library for selection of antibodies to a wide variety of
164. Larroche C, Chanseaud Y, Garcia de la Pena-Lefebvre P, et al: antigens. BMC Biotechnol 9:1–16, 2009.
Mechanisms of intravenous immunoglobulin action in the treatment 190. Greenfield EA: Ch 7. Generating monoconal antibodies, a laboratory
of autoimmune disorders. Biodrugs 16:47, 2002. maunual, Second ed, 2014, Cold Spring Harbor Press.